References

1. 1.
   YE H，ROBAK L A，YU M，et al.Genetics and pathogenesis of Parkinson's Syndrome［J］.Annu Rev Pathol，2023，18：95-121.
2. 2.
   WEINTRAUB D，AARSLAND D，CHAUDHURI K R，et al.The neuropsychiatry of Parkinson's disease：Advances and challenges［J］.Lancet Neurol，2022，21（1）：89-102.
3. 3.
   COHEN J，MATHEW A，DOURVETAKIS K D，et al.Recent research trends in neuroinflammatory and neurodegenerative disorders［J］.Cells，2024，13（6）：511.
4. 4.
   LINDSAY H G，HENDRIX C J，GONZALEZ MURCIA J D，et al.The role of atypical chemokine receptors in neuroinflammation and neurodegenerative disorders［J］.Int J Mol Sci，2023，24（22）：16493.
5. 5.
   TOFARIS G K.Initiation and progression of α-Synuclein pathology in Parkinson's disease［J］.Cell Mol Life Sci，2022，79（4）：210.
6. 6.
   CHHETRI J K，MEI S，WANG C，et al.New horizons in Parkinson's disease in older populations［J］.Age Ageing，2023，52（10）：afad186.
7. 7.
   ARMSTRONG M J，OKUN M S.Diagnosis and treatment of parkinson disease：A review［J］.JAMA，2020，323（6）：548-560.
8. 8.
   BLOEM B R，OKUN M S，KLEIN C.Parkinson's disease［J］.Lancet，2021，397（10291）：2284-2303.
9. 9.
   GEORGE M，THARAKAN M，CULBERSON J，et al.Role of Nrf2 in aging，Alzheimer's and other neurodegenerative diseases［J］.Ageing Res Rev，2022，82：101756.
10. 10.
    ZHANG C，SHAO W，YUAN H，et al.Engineered extracellular vesicle-based nanoformulations that coordinate neuroinflammation and immune homeostasis，enhancing Parkinson's disease therapy［J］.ACS Nano，2024，18（34）：23014-23031.
11. 11.
    CHAKKITTUKANDIYIL A，SAJINI D V，KARUPPAIAH A，et al.The principal molecular mechanisms behind the activation of Keap1/Nrf2/ARE pathway leading to neuroprotective action in Parkinson's disease［J］.Neurochem Int，2022，156：105325.
12. 12.
    JIN X，DONG W，CHANG K，et al.Research on the signaling pathways related to the intervention of traditional Chinese medicine in Parkinson's disease：A literature review［J］.J Ethnopharmacol，2024，326：117850.
13. 13.
    DAYALAN NAIDU S，DINKOVA-KOSTOVA A T.Keap1，a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease［J］.Open Biol，2020，10（6）：200105.
14. 14.
    KOPACZ A，KLOSKA D，FORMAN H J，et al.Beyond repression of Nrf2：An update on Keap1［J］.Free Radic Biol Med，2020，157：63-74.
15. 15.
    TU W，WANG H，LI S，et al.The anti-inflammatory and anti-oxidant mechanisms of the Keap1/Nrf2/ARE signaling pathway in chronic diseases［J］.Aging Dis，2019，10（3）：637-651.
16. 16.
    MORGENSTERN C，LASTRES-BECKER I，DEMIRDÖĞEN B C，et al.Biomarkers of Nrf2 signalling：Current status and future challenges［J］.Redox Biol，2024，72：103134.
17. 17.
    MALHOTRA D，PORTALES-CASAMAR E，SINGH A，et al.Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis［J］.Nucleic Acids Res，2010，38（17）：5718-5734.
18. 18.
    IEGRE J，KRAJCOVICOVA S，GUNNARSSON A，et al.A cell-active cyclic peptide targeting the Nrf2/Keap1 protein-protein interaction［J］.Chem Sci，2023，14（39）：10800-10805.
19. 19.
    LIU S，PI J，ZHANG Q.Signal amplification in the Keap1-Nrf2-ARE antioxidant response pathway［J］.Redox Biol，2022，54：102389.
20. 20.
    ZGORZYNSKA E，DZIEDZIC B，WALCZEWSKA A.An overview of the Nrf2/ARE pathway and its role in neurodegenerative diseases［J］.Int J Mol Sci，2021，22（17）：9592.
21. 21.
    MAGESH S，CHEN Y，HU L.Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents［J］.Med Res Rev，2012，32（4）：687-726.
22. 22.
    RAGHUNATH A，SUNDARRAJ K，NAGARAJAN R，et al.Antioxidant response elements：Discovery，classes，regulation and potential applications［J］.Redox Biol，2018，17：297-314.
23. 23.
    SUN H J，DING S，GUAN D X，et al.Nrf2/Keap1 pathway in countering arsenic-induced oxidative stress in mice after chronic exposure at environmentally-relevant concentrations［J］.Chemosphere，2022，303（Pt 3）：135256.
24. 24.
    KURZHAGEN J T，NOEL S，LEE K，et al.T cell Nrf2/Keap1 gene editing using CRISPR/Cas9 and experimental kidney ischemia-reperfusion injury［J］.Antioxid Redox Signal，2023，38（13/15）：959-973.
25. 25.
    YAMAMOTO M，KENSLER T W，MOTOHASHI H.The Keap1-Nrf2 system：A thiol-based sensor-effector apparatus for maintaining redox homeostasis［J］.Physiol Rev，2018，98（3）：1169-1203.
26. 26.
    LI J，WANG T，LIU P，YANG F，et al.Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/Akt-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD［J］.Food Funct，2021，12（9）：3898-3918.
27. 27.
    YU C，XIAO J H.The Keap1-Nrf2 system：A mediator between oxidative stress and aging［J］.Oxid Med Cell Longev，2021，2021：6635460.
28. 28.
    LIU Y Y，PENG T，YAO J，et al.Neuroprotection of natural products based on Keap1/Nrf2/ARE signaling pathway：A review［J］.Chin J Exp Tradit Med Form，2023，29（7）：262-273.
29. 29.
    NAIR B，ADITHYA J K，CHANDRABABU G，et al.Modulation of carcinogenesis with selected GRAS nutraceuticals via Keap1-Nrf2 signaling pathway［J］.Phytother Res，2023，37（10）：4398-4413.
30. 30.
    DHYANI N，TIAN C，GAO L，et al.Nrf2-Keap1 in cardiovascular disease：Which is the cart and which the horse？［J］.Physiology （Bethesda），2024，39（5）：14.
31. 31.
    TIBERI J，CESARINI V，STEFANELLI R，et al.Sex differences in antioxidant defence and the regulation of redox homeostasis in physiology and pathology［J］.Mech Ageing Dev，2023，211：111802.
32. 32.
    JIANG T，SUN Q，CHEN S.Oxidative stress：A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease［J］.Prog Neurobiol，2016，147：1-19.
33. 33.
    TRIST B G，HARE D J，DOUBLE K L.Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease［J］.Aging Cell，2019，18（6）：e13031.
34. 34.
    SIMON D K，TANNER C M，BRUNDIN P.Parkinson disease epidemiology，pathology，genetics，and pathophysiology［J］.Clin Geriatr Med，2020，36（1）：1-12.
35. 35.
    PICCA A，GUERRA F，CALVANI R，et al.Mitochondrial dysfunction，protein misfolding and neuroinflammation in Parkinson's disease：Roads to biomarker discovery［J］.Biomolecules，2021，11（10）：1508.
36. 36.
    NIU Y，ZHANG J，DONG M.Nrf2 as a potential target for Parkinson's disease therapy［J］.J Mol Med （Berl），2021，99（7）：917-931.
37. 37.
    BAXTER P S，MÁRKUS N M，DANDO O，et al.Targeted de-repression of neuronal Nrf2 inhibits α-Synuclein accumulation［J］.Cell Death Dis，2021，12（2）：218.
38. 38.
    ZHAO H，SONG J，WANG T，et al.Selenium nanoparticles decorated with polysaccharides from Sargassum fusiforme protects against 6-OHDA-induced neurotoxicity in PC12 cells and rat model of Parkinson's disease［J］.Nanomedicine，2024，59：102755.
39. 39.
    THIRUVENGADAM M，VENKIDASAMY B，SUBRAMANIAN U，et al.Bioactive compounds in oxidative stress-mediated diseases：Targeting the Nrf2/ARE signaling pathway and epigenetic regulation［J］.Antioxidants （Basel），2021，10（12）：1859.
40. 40.
    KIM S，INDU VISWANATH A N，PARK J H，et al.Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model［J］.Neuropharmacology，2020，167：107989.
41. 41.
    MAROGIANNI C，SOKRATOUS M，DARDIOTIS E，et al.Neurodegeneration and inflammation-an interesting interplay in Parkinson's disease［J］.Int J Mol Sci，2020，21（22）：8421.
42. 42.
    PAJARES M，I ROJO A ，MANDA G，et al.Inflammation in Parkinson's disease：Mechanisms and therapeutic implications［J］.Cells，2020，9（7）：1687.
43. 43.
    HUANG B，HU G，ZONG X，et al.α-Cyperone protects dopaminergic neurons and inhibits neuroinflammation in LPS-induced Parkinson's disease rat model via activating Nrf2/HO-1 and suppressing NF-κB signaling pathway［J］.Int Immunopharmacol，2023，115：109698.
44. 44.
    ZHENG T，ZHANG Z.Activated microglia facilitate the transmission of α-Synuclein in Parkinson's disease［J］.Neurochem Int，2021，148：105094.
45. 45.
    SAHA S，BUTTARI B，PROFUMO E，et al.A perspective on Nrf2 signaling pathway for neuroinflammation：A potential therapeutic target in Alzheimer's and Parkinson's diseases［J］.Front Cell Neurosci，2021，15：787258.
46. 46.
    JAYARAM S，KRISHNAMURTHY P T.Role of microgliosis，oxidative stress and associated neuroinflammation in the pathogenesis of Parkinson's disease：The therapeutic role of Nrf2 activators［J］.Neurochem Int，2021，145：105014.
47. 47.
    RAJAN S，TRYPHENA K P，KHAN S，et al.Understanding the involvement of innate immunity and the Nrf2-NLRP3 axis on mitochondrial health in Parkinson's disease［J］.Ageing Res Rev，2023，87：101915.
48. 48.
    URUNO A，YAMAMOTO M.The Keap1-Nrf2 system and neurodegenerative diseases［J］.Antioxid Redox Signal，2023，38（13/15）：974-988.
49. 49.
    KOBAYASHI E H，SUZUKI T，FUNAYAMA R，et al.Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription［J］.Nat Commun，2016，7：11624.
50. 50.
    IORIO R，CELENZA G，PETRICCA S.Multi-target effects of β-caryophyllene and carnosic acid at the crossroads of mitochondrial dysfunction and neurodegeneration：From oxidative stress to microglia-mediated neuroinflammation［J］.Antioxidants （Basel），2022，11（6）：1199.
51. 51.
    MENG H W，SHEN Z B，MENG X S，et al.Novel flavonoid 1，3，4-oxadiazole derivatives ameliorate MPTP-induced Parkinson's disease via Nrf2/NF-κB signaling pathway［J］.Bioorg Chem，2023，138：106654.
52. 52.
    LI R，JIA Z，ZHU H.Regulation of Nrf2 signaling［J］.React Oxyg Species（Apex），2019，8（24）：312-322.
53. 53.
    SAHA S，BUTTARI B，PANIERI E，et al.An overview of Nrf2 signaling pathway and its role in inflammation［J］.Molecules，2020，25（22）：5474.
54. 54.
    XU L L，WU Y F，YAN F，et al.5-（3，4-Difluorophenyl）-3-（6-methylpyridin-3-yl）-1，2，4-oxadiazole （DDO-7263），a novel Nrf2 activator targeting brain tissue，protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress［J］.Free Radic Biol Med，2019，134：288-303.
55. 55.
    PARK J E，LEEM Y H，PARK J S，et al.Astrocytic Nrf2 mediates the neuroprotective and anti-inflammatory effects of nootkatone in an MPTP-induced Parkinson's disease mouse model［J］.Antioxidants （Basel），2023，12（11）：1999.
56. 56.
    GIELECIŃSKA A，KCIUK M，YAHYA E B，et al.Apoptosis，necroptosis，and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents？［J］.Biochim Biophys Acta Rev Cancer，2023，1878（6）：189024.
57. 57.
    BEKKER M，ABRAHAMS S，LOOS B，et al.Can the interplay between autophagy and apoptosis be targeted as a novel therapy for Parkinson's disease？［J］.Neurobiol Aging，2021，100：91-105.
58. 58.
    XU Y，MENG X，ZHAO W X，et al.Neuroprotective effect of ginsenoside Re on drosophila model of Parkinson's disease［J］.Chin J Chin Mater Med，2023，48（7）：1927-1935.
59. 59.
    HE J，ZHANG X，LIAN C，et al.Keap1/Nrf2 axis regulates H₂O₂-induced apoptosis of pancreatic β-cells［J］.Gene，2019，691：8-17.
60. 60.
    XUE Y，WANG A Z.DJ-1 plays a neuroprotective role in SH-SY5Y cells by modulating Nrf2 signaling in response to lidocaine-mediated oxidative stress and apoptosis［J］.Kaohsiung J Med Sci，2020，36（8）：630-639.
61. 61.
    KONG Q，DENG H，LI C，et al.Sustained high expression of Nrf2 and its target genes induces dysregulation of cellular proliferation and apoptosis is associated with arsenite-induced malignant transformation of human bronchial epithelial cells［J］.Sci Total Environ，2021，756：143840.
62. 62.
    HU K，ZHU S，WU F，et al.Aureusidin ameliorates 6-OHDA-induced neurotoxicity via activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway in SH-SY5Y cells and Caenorhabditis elegans［J］.Chem Biol Interact，2024，387：110824.
63. 63.
    DIXON S J，LEMBERG K M，LAMPRECHT M R，et al.Ferroptosis：An iron-dependent form of nonapoptotic cell death［J］.Cell，2012，149（5）：1060-1072.
64. 64.
    CHU J，LI J，SUN L，et al.The role of cellular defense systems of ferroptosis in Parkinson's disease and Alzheimer's disease［J］.Int J Mol Sci，2023，24（18）：14108.
65. 65.
    MANISCALCHI A，BENZI JUNCOS O N，CONDE M A，et al.New insights on neurodegeneration triggered by iron accumulation：Intersections with neutral lipid metabolism，ferroptosis，and motor impairment［J］.Redox Biol，2024，71：103074.
66. 66.
    DING X S，GAO L，HAN Z，et al.Ferroptosis in Parkinson's disease：Molecular mechanisms and therapeutic potential［J］.Ageing Res Rev，2023，91：102077.
67. 67.
    COSTA I，BARBOSA D J，BENFEITO S，et al.Molecular mechanisms of ferroptosis and their involvement in brain diseases［J］.Pharmacol Ther，2023，244：108373.
68. 68.
    SUN J，LIN X M，LU D H，et al.Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons［J］.J Clin Invest，2023，133（10）：e165228.
69. 69.
    TANG D，CHEN X，KANG R，et al.Ferroptosis：Molecular mechanisms and health implications［J］.Cell Res，2021，31（2）：107-125.
70. 70.
    ANANDHAN A，CHEN W ，NGUYEN N，et al.α-Syn overexpression，Nrf2 suppression，and enhanced ferroptosis create a vicious cycle of neuronal loss in Parkinson's disease［J］.Free Radic Biol Med，2022，192：130-140.
71. 71.
    YAO Y，LI P S，JIANG S，et al.A mechanism study on the antioxidant pathway of Keap1-Nrf2-ARE inhibiting ferroptosis in dopaminergic neurons［J］.Curr Mol Med，2025，25（1）：37-44..
72. 72.
    SUN Y，HE L，WANG T，et al.Activation of p62-Keap1-Nrf2 pathway protects 6-hydroxydopamine-induced ferroptosis in dopaminergic cells［J］.Mol Neurobiol，2020，57（11）：4628-4641.
73. 73.
    SUBRAMANIAM S R，CHESSELET M F.Mitochondrial dysfunction and oxidative stress in Parkinson's disease［J］.Prog Neurobiol，2013，106-107：17-32.
74. 74.
    ELDEEB M A，THOMAS R A，RAGHEB M A，et al.Mitochondrial quality control in health and in Parkinson's disease［J］.Physiol Rev，2022，102（4）：1721-1755.
75. 75.
    BRILLO V，CHIEREGATO L，LEANZA L，et al.Mitochondrial dynamics，ROS，and cell signaling：A blended overview［J］.Life （Basel），2021，11（4）：332.
76. 76.
    JAMWAL S，BLACKBURN J K，ELSWORTH J D.PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders［J］.Pharmacol Ther，2021，219：107705.
77. 77.
    BENTO-PEREIRA C，DINKOVA-KOSTOVA A T.Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson's disease［J］.Med Res Rev，2021，41（2）：785-802.
78. 78.
    GUO B，ZHENG C，CAO J，et al.Tetramethylpyrazine nitrone exerts neuroprotection via activation of PGC-1α/Nrf2 pathway in Parkinson's disease models［J］.J Adv Res，2024，64：195-211.
79. 79.
    MURAKAMI S，KUSANO Y，OKAZAKI K，et al.Nrf2 signalling in cytoprotection and metabolism［J］.Br J Pharmacol，2026，183（1）：101-114.
80. 80.
    CHEN Y，ZHU Z，YAN Y，et al.P7C3 suppresses astrocytic senescence to protect dopaminergic neurons：Implication in the mouse model of Parkinson's disease［J］.CNS Neurosci Ther，2024，30（7）：e14819.
81. 81.
    SHANG X L，WANG Y，XU C C，et al.Mechanism of traditional Chinese medicine in prevention and treatment of Parkinson's disease：A review［J］.Chin J Exp Tradit Med Form，2023，29（17）：248-259.
82. 82.
    BARBALHO S M，DIREITO R，LAURINDO L F，et al.Ginkgo biloba in the aging process：A narrative review［J］.Antioxidants （Basel），2022，11（3）：525.
83. 83.
    ADEBAYO O G，ADUEMA W，EMMANUEL M U，et al.The anti-parkinson potential of Gingko biloba-supplement mitigates cortico-cerebellar degeneration and neuropathobiological alterations via inflammatory and apoptotic mediators in mice［J］.Neurochem Res，2022，47（8）：2211-2229.
84. 84.
    YAN T，MAO Q，ZHANG X，et al.Schisandra chinensis protects against dopaminergic neuronal oxidative stress，neuroinflammation and apoptosis via the BDNF/Nrf2/NF-κB pathway in 6-OHDA-induced Parkinson's disease mice［J］.Food Funct，2021，12（9）：4079-4091.
85. 85.
    MASAKI Y，IZUMI Y，MATSUMURA A，et al.Protective effect of Nrf2-ARE activator isolated from green perilla leaves on dopaminergic neuronal loss in a Parkinson's disease model［J］.Eur J Pharmacol，2017，798：26-34.
86. 86.
    GU W，SUN Z X，JIA H L，et al.Effect of Rhodiola injection on treatment efficacy and oxidative stress indicators related to serum DJ-1/Nrf2 pathway in the patients with Parkinson's disease［J］.J Clin Exp Med，2024，23（3）：254-258.
87. 87.
    LIN Z H，LIU Y，XUE N J，et al.Quercetin protects against MPP（+）/MPTP-induced dopaminergic neuron death in Parkinson's disease by inhibiting ferroptosis［J］.Oxid Med Cell Longev，2022，2022：7769355.
88. 88.
    JIANG Y，XIE G，ALIMUJIANG A，et al.Protective effects of querectin against MPP（+）-induced dopaminergic neurons injury via the Nrf2 signaling pathway［J］.Front Biosci：Landmark Ed，2023，28（3）：42.
89. 89.
    LI X，ZHANG J，ZHANG X，et al.Puerarin suppresses MPP（+）/MPTP-induced oxidative stress through an Nrf2-dependent mechanism［J］.Food Chem Toxicol，2020，144：111644.
90. 90.
    SHIRGADWAR S M，KUMAR R，PREETI K，et al.Neuroprotective effect of phloretin in Rotenone-induced mice model of Parkinson's disease：Modulating mTOR-Nrf2-p62 mediated autophagy-oxidative stress crosstalk［J］.J Alzheimers Dis，2023，94（s1）：S109-S124.
91. 91.
    HUANG J，ZHANG X，YANG X，et al.Baicalin exerts neuroprotective actions by regulating the Nrf2-NLRP3 axis in toxin-induced models of Parkinson's disease［J］.Chem Biol Interact，2024，387：110820.
92. 92.
    ZHOU Q，CHEN B，XU Y，et al.Geniposide protects against neurotoxicity in mouse models of rotenone-induced Parkinson's disease involving the mTOR and Nrf2 pathways［J］.J Ethnopharmacol，2024，318（Pt A）：116914.
93. 93.
    FAN W，ZHOU J.Icariside Ⅱ suppresses ferroptosis to protect against MPP（+）-Induced Parkinson's disease through Keap1/Nrf2/GPx4 signaling［J］.Chin J Physiol，2023，66（6）：437-445.
94. 94.
    RATHORE A S，SINGH S S，BIRLA H，et al.Curcumin modulates p62-Keap1-Nrf2-mediated autophagy in rotenone-induced Parkinson's disease mouse models［J］.ACS Chem Neurosci，2023，doi：.
95. 95.
    LI H，SHEN Y，XIAO H，et al.Resveratrol attenuates rotenone-induced inflammation and oxidative stress via STAT1 and Nrf2/Keap1/SLC7A11 pathway in a microglia cell line［J］.Pathol Res Pract，2021，225：153576.
96. 96.
    GU S C，XIE Z G，GU M J，et al.Myricetin mitigates motor disturbance and decreases neuronal ferroptosis in a rat model of Parkinson's disease［J］.Sci Rep，2024，14（1）：15107.
97. 97.
    FU R H，TSAI C W，LIU S P，et al.Neuroprotective capability of narcissoside in 6-OHDA-exposed Parkinson's disease models through enhancing the MiR200a/Nrf-2/GSH axis and mediating MAPK/Akt associated signaling pathway［J］.Antioxidants （Basel），2022，11（11）：2089.
98. 98.
    LI M，ZHANG J，JIANG L，et al.Neuroprotective effects of morroniside from Cornus officinalis sieb.et zucc against Parkinson's disease via inhibiting oxidative stress and ferroptosis［J］.BMC Complement Med Ther，2023，23（1）：218.
99. 99.
    ZHOU Y，WANG X，YING W，et al.Cryptotanshinone attenuates inflammatory response of microglial cells via the Nrf2/HO-1 pathway［J］.Front Neurosci，2019，13：852.
100. 100.
     CHANG W H，HSU H T，LIN C C，et al.Linalool，a fragrance compound in plants，protects dopaminergic neurons and improves motor function and skeletal muscle strength in experimental models of Parkinson's disease［J］.Int J Mol Sci，2024，25（5）：2514.
101. 101.
     PRASERTSUKSRI P，KRAOKAEW P，PRANWEERAPAIBOON K，et al.Neuroprotection of andrographolide against neurotoxin MPP（+）-induced apoptosis in SH-SY5Y cells via activating mitophagy，autophagy，and antioxidant activities［J］.Int J Mol Sci，2023，24（10）：8528.
102. 102.
     ZHANG J，BAI Q，WEN Q，et al.Paeoniflorin protects 1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine-induced Parkinson's disease mice by inhibiting oxidative stress and neuronal apoptosis through activating the Nrf2/HO-1 signaling pathway［J］.Neuroreport，2023，34（5）：255-266.
103. 103.
     JIANG G，HU Y，LIU L，et al.Gastrodin protects against MPP（+）-induced oxidative stress by up regulates heme oxygenase-1 expression through p38 MAPK/Nrf2 pathway in human dopaminergic cells［J］.Neurochem Int，2014，75：79-88.
104. 104.
     ZHANG C，ZHAO M，WANG B，et al.The Nrf2-NLRP3-Caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson's disease［J］.Redox Biol，2021，47：102134.
105. 105.
     PINGALE T D，GUPTA G L.Oleanolic acid-based therapeutics ameliorate rotenone-induced motor and depressive behaviors in parkinsonian male mice via controlling neuroinflammation and activating Nrf2-BDNF-dopaminergic signaling pathways［J］.Toxicol Mech Methods，2024，34（4）：335-349.
106. 106.
     YANG C，MO Y，XU E，et al.Astragaloside Ⅳ ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson's disease mouse model［J］.Int Immunopharmacol，2019，75：105651.
107. 107.
     KAJI H，MATSUI-YUASA I，MATSUMOTO K，et al.Sesaminol prevents Parkinson's disease by activating the Nrf2-ARE signaling pathway［J］.Heliyon，2020，6（11）：e05342.
108. 108.
     PENG S，CHEN Y，WANG R，et al.Z-ligustilide provides a neuroprotective effect by regulating the phenotypic polarization of microglia via activating Nrf2-TrxR axis in the Parkinson's disease mouse model［J］.Redox Biol，2024，76：103324.
109. 109.
     SHEN J，CHEN S，LI X，et al.Salidroside mediated the Nrf2/GPx4 pathway to attenuates ferroptosis in Parkinson's disease［J］.Neurochem Res，2024，49（5）：1291-1305.
110. 110.
     INTHANON S，DEJKRIENGKRAIKUL P，YODKEEREE S.Notopterol suppresses IL-17-induced proliferation and invasion of A549 lung adenocarcinoma cells via modulation of STAT3，NF-κB，and AP-1 activation［J］.Int J Mol Sci，2023，24（20）：15057.
111. 111.
     HUA P，LIANG R，TU Y，et al.Reactive oxygen species and nitric oxide scavenging nanoparticles alleviating rheumatoid arthritis through adjusting the seeds and growing soils［J］.Acta Pharm Sin B，2023，13（12）：5016-5029.
112. 112.
     YE B，HE D，HU J，et al.Notopterol inhibits LPS-induced inflammation in BV-2 cells via Akt/Nrf2/HO-1 signaling axis［J］.Int Immunopharmacol，2023，120：110334.
113. 113.
     LI Q，SUN H，LIU S，et al.Ginsenoside Rk₁ inhibits HeLa cell proliferation through an endoplasmic reticulum signaling pathway［J］.J Ginseng Res，2023，47（5）：645-653.
114. 114.
     SHE L，SUN J，XIONG L，et al.Ginsenoside RK₁ improves cognitive impairments and pathological changes in Alzheimer's disease via stimulation of the AMPK/Nrf2 signaling pathway［J］.Phytomedicine，2024，122：155168.
115. 115.
     REN Y，YE D，DING Y，et al.Ginsenoside Rk₁ prevents 1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine-induced Parkinson's disease via activating silence information regulator 3-mediated Nrf2/HO-1 signaling pathway［J］.Hum Exp Toxicol，2023，42：9603271231220610.
116. 116.
     CAO R，WANG Y，ZHOU Y，et al.Advanced researches of traditional uses，phytochemistry，pharmacology，and toxicology of medical Uncariae Ramulus Cum Uncis［J］.J Ethnopharmacol，2024，325：117848.
117. 117.
     ZHANG C，ZHOU J，ZHUO L，et al.The TLR4/NF-κB/NLRP3 and Nrf2/HO-1 pathways mediate the neuroprotective effects of alkaloids extracted from Uncaria rhynchophylla in Parkinson's disease［J］.J Ethnopharmacol，2024，333：118391.
118. 118.
     SHENG X，YANG S，WEN X，et al.Correction：Neuroprotective effects of Shende'an tablet in the Parkinson's disease model［J］.Chin Med，2024，19（1）：106.
119. 119.
     PAN T，XIAO Q，FAN H J，et al.Effect and possible mechanism of Wuzi Yanzong pill on motor function of neurons in Parkinson's disease mice［J］.Med J Chin PLA，2024，49（5）：550-556.
120. 120.
     QIN W，BI Y，LIU D S，et al.Effect of Zhengan Xifeng decoction on Parkinson's disease mice induced by 1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine through Nrf2/HO-1 pathway［J］.J Qiqihar Med Coll，2022，43（24）：2301-2304.
121. 121.
     BIAN S B.Study on the mechanism of tonifying liver and kidney herbs inregulating oxidative stress in Parkinson's disease based on Nrf2/ARE pathway［D］.Zhengzhou：Henan University of Traditional Chinese Medicine，2022.
122. 122.
     LU J，HUANG Q，ZHANG D，et al.The protective effect of Didang Tang against AlCl₃-induced oxidative stress and apoptosis in PC12 cells through the activation of SIRT1-mediated Akt/Nrf2/HO-1 pathway［J］.Front Pharmacol，2020，11：466.
123. 123.
     CHEN Q.Mechanism of Bushen Huoxue on Nrf2 mediated antioxidant pathway in rat Parkinson's disease model［D］.Beijing：Chinese People's Liberation Army （PLA） Medical School，2017.
124. 124.
     LI N，GUO Y，GONG Y，et al.The anti-inflammatory actions and mechanisms of acupuncture from acupoint to target organs via neuro-immune regulation［J］.J Inflamm Res，2021，14：7191-7224.
125. 125.
     BAO X L，LI Y Y，WANG Y，et al.Mechanism of electroacupuncture against oxidative stress in a mouse model of Parkinson's disease by activating the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway［J］.J Anhui Univ Chin Med，2024，43（2）：32-37.
126. 126.
     ZHENG H S.The mechanism of electroacupuncture-mediated improvementof Parkinson's disease by inhibiting ferroptosis throughactivating Nrf2/GPx4 signal pathway［D］.Xianyang：Shaanxi University of Chinese Medicine，2022.
127. 127.
     ZHANG X L，HU M N，RONG Z，et al.Effect of electroacupuncture on Nrf2/NLRP3/Caspase-1 pathway mediated-pyroptosis in mice with Parkinson's disease［J］.Acupunct Res，2024，49（1）：15-22.
128. 128.
     LIU X L，LU J，TIAN Y，et al.Effect and mechanism of moxibustion on oxidative stress injury in rats with Parkinson's disease by activating Nrf2/ARE pathway［J］.Chin Acupunct Moxib，2020，40（8）：857-862.